BLA 761046 · Merck Sharp Dohme
Zinplava
Bezlotoxumab · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: May 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Oct 21, 2016
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
11
3 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Bezlotoxumab" as an intervention, any sponsor and status, largest first.
- A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01241552 · 1,452 participants · Start Oct 10, 2011 · Primary completion Dec 9, 2014
Drug: MK-3415; MK-6072 and 3 more · For: Clostridium Difficile Infection
- A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01513239 · 1,203 participants · Start Feb 1, 2012 · Primary completion May 22, 2015
Drug: MK-6072; MK-3415A and 2 more · For: Clostridium Difficile Infection
- Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03182907 · 148 participants · Start Mar 27, 2018 · Primary completion May 12, 2022
Drug: Bezlotoxumab; Placebo and 1 more · For: Clostridium Difficile Infection
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 75 sites in all
- Bezlotoxumab Efficacy and Tolerability in Cancer PatientStatus unknown
Cooper Norcross HealthAcademic, hospital or other
NCT04415918 · 132 participants (planned) · Start Jul 1, 2020 · Primary completion Jul 1, 2021
Drug: Bezlotoxumab Injection · For: Clostridium Difficile Infection Recurrence
Brigham and Women's HospitalAcademic, hospital or other
NCT03829475 · 61 participants · Start Jan 1, 2020 · Primary completion Aug 3, 2023
Drug: Bezlotoxumab; Placebo and 1 more · For: Inflammatory Bowel Diseases; Clostridium Difficile Infection
Sites: Boston, Massachusetts
- Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile InfectionCompleted
Hellenic Institute for the Study of SepsisAcademic, hospital or other
NCT05304715 · 44 participants · Start Apr 13, 2022 · Primary completion Jun 4, 2023
Drug: Bezlotoxumab; Normal saline 0.9% or 5% dextrose water · For: Clostridioides Difficile Infection; Stool Microbiome; Organ Dysfunction Syndrome and 2 more
Sites: Alexandroupoli, Greece; Athens, Greece; Ioannina, Greece · 11 sites in all
David Binion, MDAcademic, hospital or other
NCT04626947 · 19 participants · Start Oct 14, 2021 · Primary completion Apr 24, 2024
Drug: Bezlotoxumab · For: Inflammatory Bowel Diseases; Ulcerative Colitis; Crohn Disease and 1 more
Sites: Pittsburgh, Pennsylvania
Ohio State UniversityAcademic, hospital or other
NCT03756454 · 5 participants · Start Aug 19, 2019 · Primary completion May 23, 2022
Drug: Bezlotoxumab · For: Clostridia Difficile Colitis; Clostridium; Sepsis
Sites: Columbus, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zinplava (Bezlotoxumab)
2024 spending
$549K
Beneficiaries
138
141 claims
Per beneficiary
$3,975
$90.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $267,790 |
| 2021 | $421,797 |
| 2022 | $602,183 |
| 2023 | $631,513 |
| 2024 | $548,526 |
Part B: Zinplava (Bezlotoxumab) · HCPCS J0565
2024 spending
$7.1M
Beneficiaries
1,833
1,862 claims
Per beneficiary
$3,886
2024 ASP limit $39.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,702,789 |
| 2021 | $3,692,046 |
| 2022 | $6,480,136 |
| 2023 | $6,788,170 |
| 2024 | $7,122,966 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Predicted Bezlotoxumab Exposure in Patients Who Have Received a Hematopoietic Stem Cell Transplant.
de Almeida C, Wong M, Kleijn HJ, et al. · Clin Ther 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH, Gerding DN, Poxton IR, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
Prabhu VS, Dubberke ER, Dorr MB, et al. · Clin Infect Dis 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
Alhifany AA, Almutairi AR, Almangour TA, et al. · BMJ Open 2019 · Comparative Study, Network Meta-Analysis
- Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Gerding DN, Kelly CP, Rahav G, et al. · Clin Infect Dis 2018 · Clinical Trial, Phase III, Multicenter Study
- A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection.
Psarrakis C, Tziolos NR, Matzarakis V, et al. · Cell Rep Med 2026 · Randomized Controlled Trial
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.